Last reviewed · How we verify
INF108F probiotic
INF108F is a live biotherapeutic probiotic that modulates the gut microbiome to promote immune tolerance and reduce intestinal inflammation.
INF108F is a live biotherapeutic probiotic strain that modulates the gut microbiome and immune system to promote health. Used for Clostridium difficile infection (CDI) or related gastrointestinal conditions.
At a glance
| Generic name | INF108F probiotic |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Live biotherapeutic product (probiotic) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
As a probiotic therapeutic, INF108F contains live bacterial strains designed to restore beneficial microbiota composition and function. The organism produces metabolites and engages with intestinal epithelial and immune cells to enhance barrier function, promote regulatory T cell differentiation, and reduce pro-inflammatory responses. This mechanism aims to treat conditions driven by dysbiosis and aberrant immune activation.
Approved indications
- Ulcerative colitis (marketed/pipeline indication)
Common side effects
- Gastrointestinal symptoms (bloating, gas, abdominal discomfort)
- Transient bacteremia (rare, in immunocompromised patients)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |